Contemporary management of penile squamous cell carcinoma

Kroon, Bin B. R.; Horenblas, Simon; Nieweg, Omgo E.

doi:10.1002/jso.20170

Cited by 68 publications

(44 citation statements)

References 76 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sentinel node biopsy has bee n advocated but the management of ilioinguinal lymphadenopathy is controversial [255,302,303,305,310,311,317]. Est ablishe d lymp hatic or he mato g eno u s di sse m in ati o n r equi re s in di vi du al iz e d m u lt id i sciplin ar y mana gem ent.…”

Section: Managementmentioning

confidence: 99%

See 1 more Smart Citation

Management of penile dermatoses

Bunker¹

2006

Expert Review of Dermatology

View full text Add to dashboard Cite

KEYWORDS:Bowen's disease of the penis, Bowen oid papulosis, circumcision, dysesthesia s y ndrom es, dy sf unct ional f oreskin, erosive lichen planus, erythroplasia of Queyrat, lichen sclerosus, male d ys pare unia, nons peci fic b a l a n o p o st h i t i s, s q u a m o u s carcinoma, Zoon's balanitis M al e g en i t al de r m at ol o gy h a s b een a n eg l ec te d f i el d . M e n w i th ge n i ta l s k i n p ro b l em s ca n p re s en t t o d o ct or s (e .g ., i n u ro l og y or g e n i to u r i n a r y m ed i c i n e) w h o ar e n ot t r ai n e d or experienced in their diagnosis and management. The pathogenesis, epidemiology, n a tu r a l h i s t or y an d p r og n os i s o f m a n y m a l e g en i t al de r m at os e s -Z oo n 's b al an i t i s , er os i v e lichen planus, lichen sclerosus, nonspecific balanoposthitis, dysesthesia syndromes and ca r ci n o m a in situ -are ill-understood and treatment is not eviden ce-based. Althou gh penis cancer is rare, it should be preventable or diagnosable at an early stage, thus reducin g morbidity and mortality. Th e guiding ideology behind diagnosi s and management is to exclude sexually transmitted disease, minimize or abolish sexual and urinary dysfunction and the risk of penis cancer, and to preserve the foreskin if possible. However, much dermatological disease of the male organ can be attributed to the causes or consequences of preputial dysfunction. T h er e i s w i d e n or m al va r i at i on i n th e a n a to my o f t h e pe n i s a n d i ts r e l at i on s h i p t o th e p r ep u ce , pe rh ap s r ef l ect i n g s u s ce pt i b i l i ty to m i n o r em b r y ol o g i ca l a n om a l y. T h e for es k i n i s a de l i c at e, b u sy ti s s u e, i n cl o se c on t ac t w i thu r i n e and exposed to sexual secretions and detergents. These congenital and acquired factors can conspire to produce a dysfu nctional foreskin, often clinically expressed as male sexual dysfunction in the form of male dyspareunia.Expert Rev. Dermatol. 1(2), 24 1-26 0 (2006 )

show abstract

Section: Managementmentioning

confidence: 99%

“…The management of genital SCC is not generally the province of the dermatologist [168,255,283,284,[302][303][304][305][306][307][308][309][310][311][312]. Adequate surgical excision is required.…”

Section: Managementmentioning

confidence: 99%

Management of penile dermatoses

Bunker¹

2006

Expert Review of Dermatology

View full text Add to dashboard Cite

show abstract

“…Although rare in Western nations (incidence of 0.3-1/100,000; refs. 1, 2), PeSCCA can constitute up to 17% of malignant disease in men in the developing world (1). PeSCCA primarily affects older men (ages 50-70) and is rare in men less than 20 years of age (3).…”

Section: Introductionmentioning

confidence: 99%

“…PeSCCA has a multitude of histologic subtypes that have distinct clinical and prognostic associations (3). The presentation of PeSCCA can be either ulcerated or exophytic, and the disease shows a tendency toward lymphatic dissemination toward the inguinal nodes, with 30% to 60% of patients having palpable lymphadenopathy at presentation (1). Although surgery alone can cure approximately 80% of patients with limited lymph node involvement (4), advanced PeSCCA requires incorporation of systemic therapies in the neoadjuvant, consolidative, or adjuvant setting to improve outcomes over single modality approaches (5), although the evidence level for treatment guidelines is relatively low (6).…”

Section: Introductionmentioning

confidence: 99%

Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy

et al. 2015

View full text Add to dashboard Cite

Penile squamous cell carcinoma (PeSCCA) is a rare malignancy for which there are limited treatment options due to a poor understanding of the molecular alterations underlying disease development and progression. Therefore, we performed comprehensive, targeted next-generation sequencing to identify relevant somatic genomic alterations in a retrospective cohort of 60 fixed tumor samples from 43 PeSCCA cases (including 14 matched primary/metastasis pairs). We identified a median of two relevant somatic mutations and one highlevel copy-number alteration per sample (range, 0-5 and 0-6, respectively). Expression of HPV and p16 was detectable in 12% and 28% of patients, respectively. Furthermore, advanced clinical stage, lack of p16 expression, and MYC and CCND1 amplifications were significantly associated with shorter time to progression or PeSCCA-specific survival. Notably, four cases harbored EGFR amplifications and one demonstrated CDK4 amplification, genes for which approved and investigational targeted therapies are available. Importantly, although paired primary tumors and lymph node metastases were largely homogeneous for relevant somatic mutations, we identified heterogeneous EGFR amplification in primary tumor/lymph node metastases in 4 of 14 cases, despite uniform EGFR protein overexpression. Likewise, activating HRAS mutations occurred in 8 of 43 cases. Taken together, we provide the first comprehensive molecular PeSCCA analysis, which offers new insight into potential precision medicine approaches for this disease, including strategies targeting EGFR.

show abstract

“…A scopo terapeutico si pratica la linfadenectomia al tempo della penectomia, oppure entro tre mesi solo in caso di positività all'esame clinico dei linfonodi inguinali [8]. In caso di negatività dei linfonodi, non potendosi escludere la presenza di micrometastasi, si ricorre all'uso della biopsia dinamica del linfonodo, o dei linfonodi, sentinella (DSNB).…”

Section: Discussioneunclassified

Penis cancer: a case report

Sampalmieri¹,

Moretti²,

Pascale³

et al. 2014

CMI

View full text Add to dashboard Cite

45di sigaretta, le terapie radianti, la balanite xerotica obliterante e la predisposizione genetica [1]. Inoltre c'è una forte evidenza che HPV16 e 18 siano associati all'insorgenza di tumore in oltre il 50% dei casi [2,3].In Europa e in America la fascia d'età più colpita è quella compresa fra 40 e 70 anni, con un massimo intorno a 55 anni. INTRODUZIONEFra le varie lesioni maligne del pene, quella di gran lunga più frequente è il carcinoma squamoso; tale neoplasia origina preferibilmente, in ordine decrescente di frequenza, in corrispondenza del glande, della superficie interna del prepuzio, del solco balano-prepuziale e, più raramente, del corpo del pene.Anche se i fattori cancerogeni precisi non sono stati individuati, è stato appurato che le persone circoncise precocemente risultano protette dall'insorgenza del carcinoma; è stato altresì riscontrato che l'incidenza aumenta nel caso di condizioni socio-economiche molto disagiate e, di conseguenza, anche di cattive condizioni igieniche. A conferma di ciò si noti il ruolo che viene riconosciuto alla fimosi e all'accumulo di smegma che ne consegue tra i fattori di rischio. Si ritiene che varie altre condizioni possano favorire l'insorgenza di tale patologia, come il fumo

show abstract

Contemporary management of penile squamous cell carcinoma

Cited by 68 publications

References 76 publications

Management of penile dermatoses

Management of penile dermatoses

Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy

Penis cancer: a case report

Contact Info

Product

Resources

About